Authors

Xin Zhang*, Taisheng Liang, Jian Wang, Gang Wu, Xiangdong Luo

Departments

Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, Guangxi, China

Abstract

Objective: To study the relationship of PTEN, p53 protein and COX-2 expression with renal clear cell carcinoma (RCCC). 

Methods: Eighty-four patients with RCCC admitted to our hospital from January 2018 to January 2020 were selected as the research participants, and the prospective analysis was carried out. The expressions of PTEN, p53, COX-2 in patients and adjacent tissues, PTEN, p53 and COX-2 in different pathological features, the effect of PTEN, p53, COX-2 on the prognosis of RCCC, and the effects of PTEN, p53 and COX-2 on Caki-2 were detected. 

Results: PTEN in carcinoma tissues was lower than that in adjacent tissues (P<0.05), and p53 and COX-2 in carcinoma tissues were higher than that in adjacent tissues (P<0.05). PTEN was related to differentiation degree, clinical stage and lymph node metastasis, p53 was related to tumor size, differentiation degree and lymph node metastasis, COX-2 was related to tumor size, differentiation degree, clinical stage and lymph node metastasis (P<0.05). The prognosis of high PTEN group was better than that of low PTEN group, that of low p53 group was better than that of high p53 group, and that of low COX-2 group was better than that of high COX-2 group. The cell proliferation and invasion ability of sh-PTEN group were evidently lower than those of other two groups, while the apoptosis rate was higher than those of other two groups (P<0.05). The proliferation and invasion ability of sh-p53 and sh-COX-2 groups were evidently higher than the other two groups, while the apoptosis rate was lower than the other two groups (P<0.05). 

Conclusion: PTEN, p53 and COX-2 are closely related to the occurrence and development of RCCC, and have great potential significance as therapeutic targets of RCCC in the future.

Keywords

PTEN, p53, COX-2, renal clear cell carcinoma.

DOI:

10.19193/0393-6384_2022_3_308